TB-500

Research Papers and Clinical Trials

The available research on TB-500 (Thymosin Beta 4 17-23 Fragment) is limited, with most studies focusing on analytical detection methods rather than clinical efficacy.

Analytical and Detection Studies

The most substantial research involves laboratory analysis methods. A 2024 study published in the Journal of Chromatography examined TB-500 and its metabolites in laboratory experiments and rat models, developing methods to measure the compound and screen for wound healing activity in laboratory settings. However, specific sample sizes and detailed results were not provided in the available abstracts.

Earlier research from 2016-2017 focused primarily on detection methods for anti-doping purposes, examining how TB-500 behaves in various biological systems including human blood serum, liver and kidney tissues. A 2017 study in Analytical Biochemistry investigated the adsorption properties of TB-500 alongside other peptides of concern in sports testing.

Review Articles

Several 2026 review papers discuss TB-500 within the broader context of peptide therapies. These appear in sports medicine and orthopedic journals, addressing safety and efficacy questions around approved and unapproved peptide treatments. However, these are review articles rather than original research studies, and the specific evidence base for TB-500 is not detailed in the available abstracts.

Clinical Trials

Currently, there is one registered clinical trial (NCT07487363) recruiting participants to study TB-500 for cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease. This is a Phase 1/Phase 2 trial, but enrollment numbers, study design details, and results are not yet available.

Evidence Limitations

The research evidence for TB-500 remains quite thin. Most available studies focus on analytical methods rather than clinical outcomes, and the single ongoing clinical trial has not yet reported results. The review articles suggest ongoing interest in peptide therapies for musculoskeletal and aging-related applications, but specific clinical evidence for TB-500's safety and efficacy is not well-established in the peer-reviewed literature.

Note: This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for medical decisions.